Confirmed BOR in the dose-escalation and dose-expansion parts
| Dose-escalation part | Dose-expansion part | |||||
| Avelumab 10 mg/kg Q2W | Avelumab 800 mg QW→Q2W** plus M9241 16.8 µg/kg (n=7) | Avelumab 800 mg QW→Q2W** plus M9241 16.8 µg/kg (n=16) | ||||
| M9241 4 µg/kg (n=9) | M9241 8 µg/kg (n=7) | M9241 12 µg/kg (n=7) | M9241 16.8 µg/kg (n=6) | |||
| Confirmed BOR, n (%) | ||||||
| Complete response | 0 | 1 (14.3) | 0 | 1 (16.7) | 0 | 0 |
| Partial response | 0 | 0 | 0 | 0 | 0 | 0 |
| Stable disease | 2 (22.2) | 2 (28.6) | 2 (28.6) | 1 (16.7) | 2 (28.6) | 2 (12.5) |
| Progressive disease | 6 (66.7) | 3 (42.9) | 4 (57.1) | 2 (33.3) | 5 (71.4) | 13 (81.3) |
| Not evaluable | 1 (11.1) | 1 (14.3) | 1 (14.3) | 2 (33.3) | 0 | 1 (6.3) |
*Avelumab QW for 12 weeks then Q2W thereafter.
BOR, best overall response; QW, once a week; Q2W, every 2 weeks.